共 44 条
- [1] Siegel RL(2017)Cancer Statistics, 2017 CA Cancer J Clin 67 7-30
- [2] Miller KD(2014)Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention Cancer Epidemiol Biomark Prev 23 700-713
- [3] Jemal A(2015)Second-line treatment of metastatic gastric cancer: current options and future directions World J Gastroenterol 21 11621-11635
- [4] Karimi P(2015)Ramucirumab: a new therapy for advanced gastric cancer J Adv Pract Oncol 6 71-75
- [5] Islami F(2014)Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Lancet 383 31-39
- [6] Anandasabapathy S(2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 1224-1235
- [7] Freedman ND(2014)Clinical management of advanced gastric cancer: the role of new molecular drugs World J Gastroenterol 20 14537-14558
- [8] Kamangar F(2017)Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data J Gastric Cancer 17 132-144
- [9] Kanagavel D(2004)Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395-2403
- [10] Fedyanin M(undefined)undefined undefined undefined undefined-undefined